Tenpoint Therapeutics Seeks Regulatory UK Approval for Yuvezzi, Presbyopia Treatment

Published on July 14, 2026
LONDON and WARREN, N.J.,—Tenpoint Therapeutics, Ltd., a global commercial-stage ophthalmic pharmaceutical company focused on developing treatments to improve vision in the aging eye, has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a once- daily, dual-agent (combination) eye drop for the treatment of presbyopia in adults, according to an announcement from the company.
Continue reading on website
Other news

American Foundation for the Blind Announces 2026 Kirchner and Gund Award Honorees

July 14, 2026
WASHINGTON, D.C.—The American Foundation for the Blind (AFB) has announced the 2026 recipients of its Corinne Kirchner Research Award and Llura Gund Leadership Award. The Corinne Kirchner Research Award will be presented to Rachel Schles, Ph.D., assistant professor at Vanderbilt University; the Llura Gund Leadership Award will be presented to Marissa Miara, director of student services at Marshall

EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer

July 14, 2026
WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and developer of therapeutics for patients with serious retinal diseases, has announced the appointment of Tarek S. Hassan, MD, as senior vice president, chief strategic science officer. Dr. Hassan will report directly to Jay S. Duker, MD, president and CEO of EyePoint, and will serve as a member of the exec